DiscoverKeeping Current CMEBiomarkers, Genetics, and Anti-Amyloid Therapies for Early Stages of AD
Biomarkers, Genetics, and Anti-Amyloid Therapies for Early Stages of AD

Biomarkers, Genetics, and Anti-Amyloid Therapies for Early Stages of AD

Update: 2025-08-22
Share

Description

Using biomarker testing and APOE genotyping to determine patient eligibility for amyloid-targeting therapies.

Credit available for this activity expires: 8/19/2026

Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002844?ecd=bdc_podcast_libsyn_mscpedu

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Biomarkers, Genetics, and Anti-Amyloid Therapies for Early Stages of AD

Biomarkers, Genetics, and Anti-Amyloid Therapies for Early Stages of AD